E-resources
Peer reviewed
Open access
-
Shao, Miao; Miao, Miao; Zhang, Xia; Zhang, Xiaoying; An, Yuan; Guo, Huifang; Lei, Lingyan; Zhao, Qing; Ding, Yanjie; Lin, Jin; Wu, Rui; Yu, Feng; Li, Yucui; Miao, Huali; Zhang, Liyun; Du, Yan; Jiao, Ruiying; Pang, Lixia; Long, Li; Yao, Xueming; Shi, Xiaofei; Wang, Fei; Cui, Luping; Zhang, Lei; Liu, Shengyun; Lu, Fuai; Luo, Kangkai; Zhao, Simeng; Wang, Yongfu; Wu, Xiao; Wang, Qingwen; Liu, Hongjiang; Song, Shulin; Zhou, Xiaoyuan; Zhang, Xiaoping; Shi, Shumei; Zhu, Hong; Chen, Yao; Yu, Honglian; Wu, Jie; Yu, Ruiyun; Fan, Wenqiang; Liu, Shuang; Xu, Jian; Chen, Zhibin; Shi, Lianjie; He, Jing; Zhang, Xuewu; Li, Zhanguo; Li, Ru
Lupus science & medicine, 11/2022, Volume: 9, Issue: 1Journal Article
ObjectiveInfection is a major cause of death in patients with SLE. This study aimed to explore the infection rate in patients with SLE receiving a low dose of intravenous cyclophosphamide (IV-CYC).MethodsClinical parameters of 1022 patients with SLE from 24 hospitals in China were collected. Patients were divided into the short-interval and lower-dose (SILD, 400 mg every 2 weeks) IV-CYC group and the high-dose (HD, 500 mg/m2 of body surface area every month) IV-CYC group. The clinical data and infection rate between the two groups were compared.ResultsCompared with HD IV-CYC, the infection rate of the SILD IV-CYC group was significantly lower (13.04% vs 22.27%, p=0.001). Respiratory tract infection (10.28% vs 15.23%, p=0.046) and skin/soft tissue infection (1.78% vs 4.3%, p=0.040) were significantly decreased in the SILD IV-CYC group. Moreover, infections occurred most likely in patients with SLE with leucopenia (OR 2.266, 95% CI 1.322 to 3.887, p=0.003), pulmonary arterial hypertension (OR 2.756, 95% CI 1.249 to 6.080, p=0.012) and >15 mg/day of glucocorticoid (OR 2.220, 95% CI 1.097 to 4.489, p=0.027).ConclusionsSILD IV-CYC showed a lower frequency of infection events than high-dose IV-CYC in patients with SLE.
